{"id":992978,"date":"2026-08-10T16:45:50","date_gmt":"2026-08-10T20:45:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-reports-second-quarter-2026-financial-results-and-corporate-updates\/"},"modified":"2026-08-10T16:45:50","modified_gmt":"2026-08-10T20:45:50","slug":"bridgebio-reports-second-quarter-2026-financial-results-and-corporate-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-reports-second-quarter-2026-financial-results-and-corporate-updates\/","title":{"rendered":"BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates"},"content":{"rendered":"
\n

\n – $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby\u00ae net product revenue, with growth led by the treatment-na\u00efve segment as physicians increasingly start and keep patients on Attruby<\/em>\n <\/p>\n

\n – Attruby is the first ATTR-CM therapy associated with direct kidney protection, with post-hoc analyses published in Circulation: Heart Failure showing a profile consistent with ACE inhibitors, ARBs, and SGLT2s including an early, reversible eGFR dip, an improved chronic eGFR slope relative to placebo, and a 13.7% reduction in urinary albumin-to-creatinine ratio through Month 30; the magnitude of the acute eGFR dip was positively associated with greater early cardiovascular benefit; BridgeBio will explore the potential for Attruby to treat other orphan kidney indications<\/em>\n <\/p>\n

\n – Real-world evidence continues to differentiate Attruby from tafamidis, with an independent propensity score-matched analysis of 286 patient pairs from the TriNetX network published in JSCAI associating acoramidis with a 37% reduction in composite cardiovascular events (p=0.002) and a 34% reduction in hospitalizations (p=0.002) at six months; further independent RWE using electronic health records are expected, and we are confident Attruby will consistently demonstrate clinical superiority over tafamidis to the benefit of patients and healthcare delivery systems for which heart failure remains a top concern<\/em>\n <\/p>\n

\n –<\/em>
\n All three planned NDAs are now submitted to the FDA: BBP-418 for LGMD2I\/R9 was accepted with Priority Review (PDUFA November 27, 2026); encaleret for ADH1 was accepted with Priority Review (PDUFA May 8, 2027), with no advisory committee planned for either; oral infigratinib for achondroplasia has been submitted, with U.S. launch expected mid-2027 <\/em>\n <\/p>\n

\n – Diagnosis and awareness continue to accelerate ahead of the launches: in ADH, more than 2,200 unique patients are now identified under the dedicated ICD-10 code, at approximately 70 new diagnoses per month; in LGMD2I\/R9, BridgeBio is investing in awareness and multidisciplinary care at MDA Care Center Network sites, where we expect 85% of target physicians to be familiar with the BBP-418 profile and data by launch<\/em>\n <\/p>\n

\n – The oral encaleret and oral infigratinib franchises continue to expand beyond their first indications: RECLAIM-HP in chronic hypoparathyroidism has begun screening patients with topline data anticipated in late 2027 or early 2028, CALIBRATE-PEDS in pediatric ADH1 has completed enrollment in its first cohort, and a Phase 2 update in hypochondroplasia is expected in the second half of 2026 <\/em>\n <\/p>\n

\n – $720.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which does not include the $1 billion preferred equity financing that closed on July 1, 2026<\/em>\n <\/p>\n

\n – BridgeBio will host a Commercial Day in New York City on October 8, 2026, to discuss commercial readiness and launch strategy across its three upcoming launches
<\/em>\n <\/p>\n

PALO ALTO, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the second quarter ended June 30, 2026, and provided an update on Attruby\u2019s commercial progress.<\/p>\n

\n Pipeline Overview:<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n
\n Program<\/strong>\n <\/td>\n\n Status<\/strong>\n <\/td>\n\n Next expected milestone<\/strong>\n <\/td>\n<\/tr>\n
Acoramidis for ATTR-CM<\/td>\nApproved in U.S., E.U., Japan, Switzerland, Brazil, and U.K.<\/td>\nNew data to be shared at ESC 2026<\/td>\n<\/tr>\n
BBP-418 for LGMD2I\/R9<\/td>\nPDUFA date set for November 27, 2026 with Priority Review<\/td>\nLaunch upon FDA approval<\/td>\n<\/tr>\n
Encaleret for ADH1<\/td>\nPDUFA date set for May 8, 2027 with Priority Review; MAA submitted to EMA<\/td>\nLaunch upon FDA approval<\/td>\n<\/tr>\n
Oral infigratinib for achondroplasia<\/td>\nNDA submitted to FDA<\/td>\nFDA sets PDUFA date<\/td>\n<\/tr>\n
Oral Encaleret for chronic hypoparathyroidism<\/td>\nFirst investigational sites activated for RECLAIM-HP, Phase 3 study<\/td>\nFirst participant dosed in Q3 2026<\/td>\n<\/tr>\n
Oral infigratinib for hypochondroplasia<\/td>\nACCEL 2\/3 enrollment ongoing<\/td>\nPhase 2 clinical trial update in 2H 2026<\/td>\n<\/tr>\n
Depleter for ATTR-CM<\/td>\nDevelopment candidate nomination<\/td>\nSubmit IND to the FDA in 2027<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\u201cI’m excited by the growing body of evidence continuing to demonstrate Attruby is the drug of choice for all ATTR-CM patients, and particularly for those who are treatment-na\u00efve, including the first-ever demonstration of early, sustained kidney-protective effects in ATTR-CM alongside the cardiac benefit we’ve established. Furthermore, this was the quarter all three of our pipeline programs, BBP-418, encaleret, and infigratinib, moved from data into active regulatory review, with our first PDUFA date now set for November 27, 2026, which is a level of strategic execution and discipline I’m proud of. Finally, with the $1 billion preferred equity financing we completed, we have a balance sheet sized to run all three launches at full strength, without diverting resources from the development engine that produced them,\u201d said Neil Kumar, Ph.D., Co-Founder and CEO of BridgeBio.<\/p>\n

\n
\n Commercial Updates:<\/u>
\n <\/strong>
\n
The second quarter total revenues, net totaled $243.7 million, comprised of $222.4 million of U.S. Attruby net product revenue, $15.4 million from royalty revenue, and $5.8 million in license and services revenue.<\/p>\n

\u201cWe continue to see strong growth this quarter for Attruby with our first-line share climbing again,\u201d said Matt Outten, Chief Commercial Officer of BridgeBio. \u201cWhat comes next will continue to shape BridgeBio\u2019s next chapter as we prepare for three potential approvals in three different diseases, all with best-in-class potential, each backed by the same commercial engine that made Attruby a success. We look forward to continuing to deliver for patients and addressing the gaps within the treatment paradigm for rare disease.\u201d<\/p>\n

\n
\n Pipeline Updates:<\/u>
\n <\/strong>
\n
\n Attruby (acoramidis) \u2013 First and only near-complete (\u226590%) transthyretin (TTR) stabilizer for treatment of transthyretin amyloid cardiomyopathy (ATTR-CM):<\/strong>\n <\/p>\n